Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03747939 · ClinicalTrials.gov registry record · Phase 4
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 310
- Enrollment target
NCT03747939 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 310 participants.
The verdict
NCT03747939, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 310 participants
- Enrollment target
Study Summary
This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 285 patients worldwide will take part in this study.
Interventions
- DRUG Apremilast (CC-10004)
- OTHER Apremilast (CC-10004) Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2018-12-31 |
| Est. Completion | 2023-07-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03747939
The ClinicalTrials.gov registry entry for NCT03747939 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apremilast (CC-10004) is the first listed.
NCT03747939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03747939 about?
NCT03747939 is a clinical study titled "Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.". This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improvin...
What is the current status of trial NCT03747939?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 310 participants. The study started on 2018-12-31. Estimated completion is 2023-07-05.
What interventions are being tested in trial NCT03747939?
The interventions under investigation include: Apremilast (CC-10004) (DRUG), Apremilast (CC-10004) Placebo (OTHER).
Who is sponsoring clinical trial NCT03747939?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.